Table 3 Sites of response and progression in patients with dissociated responses, and treatment after dissociated responses in eleven patients with dissociated responses
Age (range) | Sex | ICIs | Treatment after DR | Response site | Progression site |
|---|---|---|---|---|---|
71–75 | M | Nivo | Continuation of ICIs | primary lesion | bone; new lesion |
26–30 | M | Nivo | Continuation of ICIs | primary lesion, LN (thoracic), kidney, adrenal, PM | PM; non-target lesion adrenal; new lesion |
46–50 | M | Nivo | Continuation of ICIs | PM | primary lesion; target lesion |
71–75 | M | Pemb | S1 + Bevacizumab | PM | PM; target lesion LN (thoracic);non-target lesion Liver; non-target lesion |
66–70 | M | Nivo | Continuation of ICIs | primary lesion, LN (thoracic) | adrenal; new lesion |
76–80 | M | Nivo | BSC | LN (axilla) | PM; new lesion |
46–50 | F | Nivo | Local radiotherapy | LN (abdominal), LN (axilla) | PM; target lesion LN (thoracic); non-target lesion Subcutaneous metastasis; non-target lesion |
51–55 | F | Pemb | S1 | PM | primary lesion; target lesion PM; new lesion |
41–45 | F | Nivo | Pemetrexed and local radiotherapy | LN (axilla) PM | Brain; new lesion, PM; new lesion Bone; non-target lesion |
76–80 | M | Nivo | Continuation of ICIs | primary lesion, PM | LN (thoracic); non-target lesion |
66–70 | F | Nivo | S1 | liver | primary lesion; non-target lesion PM; non-target lesion LN (thoracic); non-target lesion Liver; new lesion, LN (abdominal); new lesion |